NCT00395317 - Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) | Biotech Hunter

Enrollment

343

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2010

Conditions

Multiple Sclerosis

Interventions

OTHER

Placebo

placebo tablet

DRUG

Firategrast 150 mg

150 mg tablet

DRUG

Firategrast 300 mg

300 mg tablet

Trial Locations (79)

1001

GSK Investigational Site, Auckland

2050

GSK Investigational Site, Camperdown

2317

GSK Investigational Site, Hamar

3004

GSK Investigational Site, Drammen

3050

GSK Investigational Site, Parkville

3065

GSK Investigational Site, Fitzroy

3710

GSK Investigational Site, Skien

4313

GSK Investigational Site, Sandnes

5011

GSK Investigational Site, Woodville

5021

GSK Investigational Site, Bergen

6021

GSK Investigational Site, Wellington

8001

GSK Investigational Site, Christchurch

10625

GSK Investigational Site, Berlin

10961

GSK Investigational Site, Berlin

12167

GSK Investigational Site, Berlin

13385

GSK Investigational Site, Marseille

18147

GSK Investigational Site, Rostock

20014

GSK Investigational Site, San Sebastián

20100

GSK Investigational Site, Turku

20132

GSK Investigational Site, Milan

21013

GSK Investigational Site, Gallarate

21033

GSK Investigational Site, Dijon

22087

GSK Investigational Site, Hamburg

28007

GSK Investigational Site, Madrid

28035

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

28832

GSK Investigational Site, Achim

30625

GSK Investigational Site, Hanover

33647

GSK Investigational Site, Bielefeld

35033

GSK Investigational Site, Rennes

35745

GSK Investigational Site, Herborn

41071

GSK Investigational Site, Seville

44093

GSK Investigational Site, Nantes

45122

GSK Investigational Site, Essen

46010

GSK Investigational Site, Valencia

48903

GSK Investigational Site, Barakaldo (Vizcaya)

50767

GSK Investigational Site, Cologne

51109

GSK Investigational Site, Cologne

52349

GSK Investigational Site, Düren

53100

GSK Investigational Site, Siena

53604

GSK Investigational Site, Bad Honnef

59000

GSK Investigational Site, Lille

63003

GSK Investigational Site, Clermont-Ferrand

66013

GSK Investigational Site, Chieti

67091

GSK Investigational Site, Strasbourg

86633

GSK Investigational Site, Neuburg an der Donau

117049

GSK Investigational Site, Moscow

125101

GSK Investigational Site, Moscow

125367

GSK Investigational Site, Moscow

194291

GSK Investigational Site, Saint Petersburg

194354

GSK Investigational Site, Saint Petersburg

197022

GSK Investigational Site, Saint Petersburg

197376

GSK Investigational Site, Saint Petersburg

A-8036

GSK Investigational Site, Graz

A-6020

GSK Investigational Site, Innsbruck

N6A 5C1

GSK Investigational Site, London

K1H 8L6

GSK Investigational Site, Ottawa

J9J 0A5

GSK Investigational Site, Gatineau

J4V 2J2

GSK Investigational Site, Greenfield Park

01307

GSK Investigational Site, Dresden

04103

GSK Investigational Site, Leipzig

04157

GSK Investigational Site, Leipzig

00163

GSK Investigational Site, Rome

5211 RW

GSK Investigational Site, 's-Hertogenbosch

4818 CK

GSK Investigational Site, Breda

5623 EJ

GSK Investigational Site, Eindhoven

3435 CM

GSK Investigational Site, Nieuwegein

6162 BG

GSK Investigational Site, Sittard-geleen

5801 CE

GSK Investigational Site, Venray

80-299

GSK Investigational Site, Gdansk

60-479

GSK Investigational Site, Poznan

61-298

GSK Investigational Site, Poznan

02-097

GSK Investigational Site, Warsaw

08035

GSK Investigational Site, Barcelona

RM7 0AG

GSK Investigational Site, Romford

ST4 7LN

GSK Investigational Site, Hartshill, Stoke-on-Trent

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

NG7 2UH

GSK Investigational Site, Nottingham

S10 2JF

GSK Investigational Site, Sheffield